Roche Issues Changes to Warnings and Adverse Events
CellCept to Cary Warning for Progressive Multifocal Leukoencephalopathy
PML Cases ReportedRoche Laboratories has informed healthcare professionals of changes to the warnings and adverse reactions sections of the CellCept prescribing information. The changes are based on postmarketing data regarding cases of Progressive Multifocal Leukoencephalopathy (PML) in patients treated with CellCept.
In April, the Food and Drug Administration informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease.
JUN-26-08: Roche Issues Changes to Warnings and Adverse Events [FDA: CELLCEPT ADVERSE REACTIONS]
Legal HelpIf you or a loved one has suffered injury or damages from this product, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Class Action Law Suits
Newsworthy Law Suits
Defective Products Lawsuits
Drug & Medical Claims Lawsuits
Food & Dietary Supplement Lawsuits
Personal Injury Lawsuits
Real Estate Lawsuits
Investment Fraud Lawsuits